Literature update on valuable biomarkers in COVID-19

valuable biomarkers on covid19

In the face of this SARS-CoV-2 pandemic, we are witnessing an increasing number of publications referring to the possible use of existing biomarkers in patients with COVID-19. Applications for biomarkers are wide-ranging and can have a pivotal impact on clinical practice. However, sifting through high volumes of information is time-consuming and no easy task. 

In order to simplify this for you, we have selected relevant - and recently published - scientific articles that explore the role of various biomarkers in COVID-19. As the COVID-19 outbreak is recent and not all published articles have been peer-reviewed, we've made sure to indicate which of these references have not benefited from this peer-review.

Here below, we provide you with an overview of key messages with the help of a short summary per biomarker, as well as a summary of each article once you click on the 'Go to Summary' link.

We hope this information is interesting for you, and that in these busy times it can also enable you to support clinicians in their diagnostic and/or prognostic decisions or to improve patient selection for targeted therapies.

As you can imagine, literature is evolving rapidly, and further research will be needed to define the specific role of several biomarkers in COVID-19. In this light, this document is intended as a supporting tool and not as a means of replacing clinical decision-making, which remains the responsibility of the treating physician.    

European Society of Cardiology (ESC) Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic 



Go to summary

NICE COVID-19 rapid guideline: acute myocardial injury




Go to summary

Consult the first edition of our Literature Updates on COVID-19

Clinical predictors of mortality due to COVID-19 Based on an analysis of data of 150pts from Wuhan, China

Ruan et al. , Intensive Care Med 2019
Go to summary

The potential role of IL-6 in monitoring coronavirus disease 2019


Liu et al.


Go to summary

Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis

Lippi et al., Clinica Chimica Acta 505 (202) 190-191
Go to summary

COVID-19: consider cytokine storm syndrome and immunosuppression


Mehta et al., Lancet 2020,

Go to summary

Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19

Gao et al. doi: 
Go to summary

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Thachil et al. doi:10.111/JTH.14810
Go to summary

Detectable serum SARS-CoV-2 viral load (RNAemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Chen et al.
Go to summary

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Tang et al. doi:
Go to summary